This assumption is supported by a recently published comprehensive study on endocrine therapy resistance in advanced BC, where for example, MAPK and ER pathways have been shown to fulfill mutually exclusive tumor-growth associated functions in separate metastatic lesions from a single patient48. Here, ESR1 is linked to neoplasm.